Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Kidney Failure
Trial Timeline
Mar 1, 2010 → Jul 1, 2014
NCT ID
NCT00906204About Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction
Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction is a phase 2 stage product being developed by Sanofi for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00906204. Target conditions include End-Stage Renal Disease, Kidney Failure.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00906204 | Phase 2 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease